ALKS Q3 2024 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$378M-0.7% YoY

Gross Profit

$315M83.3% margin

Operating Income

$105M27.7% margin

Net Income

$92M24.4% margin

EPS (Diluted)

$0.55

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

$82M

Free Cash Flow

$73M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$863M

Stockholders' Equity

$1.3B

Cash & Equivalents

$396M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$378M	$381M	-0.7%
Gross Profit	$315M	$319M	-1.4%
Operating Income	$105M	$89M	+17.4%
Net Income	$92M	$48M	+93.4%

Revenue Segments

Product

$273M50%

Vivitrol

$114M21%

Aristada And Aristada Initio

$85M16%

L Y B A L V I

$75M14%